Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Internationally accepted pharmaceutical GDP regulations stipulate that distributors of pharmaceutical products and warehouses must align their operations with the specified standards
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
First advanced hybrid closed-loop insulin pump system in India features automatic insulin delivery, automatic correction boluses, and bluetooth connectivity
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
It plans launch various other health monitoring tools for smartphones, making existing devices obsolete
A total of 17 labs will be operational across the country by this month
Subscribe To Our Newsletter & Stay Updated
